Pub Date : 2024-11-01DOI: 10.1093/europace/euae280
Hiroyuki Yoshimura, Rui Providencia, Chris Finan, Amand Floriaan Schmidt, Gregory Y H Lip
Aims: The CHA2DS2VASc score is recommended for stroke risk stratification in patients with atrial fibrillation (AF). This score assigns one extra point to female sex based on evidence from the early 2000s, suggesting higher thromboembolic risk in women. This incremental risk of thromboembolism in women has decreased over time between 2007 and 2018, becoming non-significant in recent years. The objective of this study was to assess the impact of removing the sex category (Sc) from the CHA2DS2VASc score, thus validating a non-sex CHA2DS2VASc (i.e. CHA2DS2VA) score.
Methods and results: We analysed UK primary and secondary care data comprising 195 719 patients with AF followed between 1998 and 2016 (mean age: 75.9 ± 12.3 years; 49.2% women). Among 126 428 non-anticoagulated patients, we compared the CHA2DS2VASc vs. CHA2DS2VA scores every calendar year. Throughout 413 007 patient-years, a total of 8742 events of ischaemic stroke or systemic embolism were recorded. Sex differences in thromboembolic risk were not observed in the lower-risk population, but higher stroke rates were consistently seen in female patients in the higher-risk category (i.e. CHA2DS2VA ≥2). C-statistics for both CHA2DS2VA and CHA2DS2VASc scores were similar over the years (ranging from 0.62 to 0.71). With CHA2DS2VA, no relevant differences were observed in integrated discrimination improvement, and net reclassification improvement (NRI) resulted in improved reclassification (11%) in lower thromboembolic risk groups. The NRI suggested misclassification in higher thromboembolic risk patients (-7%), but this did not affect their indication for anticoagulation (i.e. patients retained their high-risk status).
Conclusion: Removing Sc from the CHA2DS2VASc score does not affect its ability to discriminate thromboembolic events in the population with AF. The use of CHA2DS2VA may simplify initial decision-making for thromboprophylaxis.
{"title":"Refining the CHA2DS2VASc risk stratification scheme: shall we drop the sex category criterion?","authors":"Hiroyuki Yoshimura, Rui Providencia, Chris Finan, Amand Floriaan Schmidt, Gregory Y H Lip","doi":"10.1093/europace/euae280","DOIUrl":"10.1093/europace/euae280","url":null,"abstract":"<p><strong>Aims: </strong>The CHA2DS2VASc score is recommended for stroke risk stratification in patients with atrial fibrillation (AF). This score assigns one extra point to female sex based on evidence from the early 2000s, suggesting higher thromboembolic risk in women. This incremental risk of thromboembolism in women has decreased over time between 2007 and 2018, becoming non-significant in recent years. The objective of this study was to assess the impact of removing the sex category (Sc) from the CHA2DS2VASc score, thus validating a non-sex CHA2DS2VASc (i.e. CHA2DS2VA) score.</p><p><strong>Methods and results: </strong>We analysed UK primary and secondary care data comprising 195 719 patients with AF followed between 1998 and 2016 (mean age: 75.9 ± 12.3 years; 49.2% women). Among 126 428 non-anticoagulated patients, we compared the CHA2DS2VASc vs. CHA2DS2VA scores every calendar year. Throughout 413 007 patient-years, a total of 8742 events of ischaemic stroke or systemic embolism were recorded. Sex differences in thromboembolic risk were not observed in the lower-risk population, but higher stroke rates were consistently seen in female patients in the higher-risk category (i.e. CHA2DS2VA ≥2). C-statistics for both CHA2DS2VA and CHA2DS2VASc scores were similar over the years (ranging from 0.62 to 0.71). With CHA2DS2VA, no relevant differences were observed in integrated discrimination improvement, and net reclassification improvement (NRI) resulted in improved reclassification (11%) in lower thromboembolic risk groups. The NRI suggested misclassification in higher thromboembolic risk patients (-7%), but this did not affect their indication for anticoagulation (i.e. patients retained their high-risk status).</p><p><strong>Conclusion: </strong>Removing Sc from the CHA2DS2VASc score does not affect its ability to discriminate thromboembolic events in the population with AF. The use of CHA2DS2VA may simplify initial decision-making for thromboprophylaxis.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-03DOI: 10.1093/europace/euae264
Birgitta Salmela, Jussi Jaakkola, Ksenia Kalatsova, Jaakko Inkovaara, Aapo L Aro, Konsta Teppo, Tero Penttilä, Olli Halminen, Jari Haukka, Jukka Putaala, Miika Linna, Pirjo Mustonen, Juha Hartikainen, K E Juhani Airaksinen, Mika Lehto
Aims: Atrial fibrillation (AF) patients frequently require active rhythm control therapy to maintain sinus rhythm and reduce symptom burden. Our study assessed whether antiarrhythmic therapies (AATs) are used disproportionately between men and women after new-onset AF.
Methods and results: The nationwide Finnish anticoagulation in AF registry-based linkage study covers all patients with new-onset AF in Finland during 2007-2018. Study outcomes included initiation of AATs in the form of antiarrhythmic drugs (AADs), cardioversion, or catheter ablation. The study population constituted of 229 565 patients (50% females). Women were older than men (76.6 ± 11.8 vs. 68.9 ± 13.4 years) and had higher prevalence of hypertension or hyperthyroidism, but lower prevalence of vascular disease, diabetes, renal disease, and cardiomyopathies than men. Overall, 17.6% of women and 25.1% of men were treated with any AAT. Women were treated with AADs more often than men in all age groups [adjusted subdistribution hazard ratio (aSHR) 1.223, 95% confidence interval (CI) 1.187-1.261]. Cardioversions were also performed less often on women than on men aged <65 years (aSHR 0.722, 95% CI 0.695-0.749), more often in patients ≥ 75 years (aSHR 1.166, 95% CI 1.108-1.227), while no difference between the sexes existed in patients aged 65-74 years. Ablations were performed less often in women aged <65 years (aSHR 0.908, 95% CI 0.826-0.998) and ≥75 years (aSHR 0.521, 95% CI 0.354-0.766), whereas there was no difference in patients aged 65-74 years.
Conclusion: Women used more AAD than men in all age groups but underwent fewer cardioversion and ablation procedures when aged <65 years.
{"title":"Sex- and age-specific differences in the use of antiarrhythmic therapies among atrial fibrillation patients: a nationwide cohort study.","authors":"Birgitta Salmela, Jussi Jaakkola, Ksenia Kalatsova, Jaakko Inkovaara, Aapo L Aro, Konsta Teppo, Tero Penttilä, Olli Halminen, Jari Haukka, Jukka Putaala, Miika Linna, Pirjo Mustonen, Juha Hartikainen, K E Juhani Airaksinen, Mika Lehto","doi":"10.1093/europace/euae264","DOIUrl":"10.1093/europace/euae264","url":null,"abstract":"<p><strong>Aims: </strong>Atrial fibrillation (AF) patients frequently require active rhythm control therapy to maintain sinus rhythm and reduce symptom burden. Our study assessed whether antiarrhythmic therapies (AATs) are used disproportionately between men and women after new-onset AF.</p><p><strong>Methods and results: </strong>The nationwide Finnish anticoagulation in AF registry-based linkage study covers all patients with new-onset AF in Finland during 2007-2018. Study outcomes included initiation of AATs in the form of antiarrhythmic drugs (AADs), cardioversion, or catheter ablation. The study population constituted of 229 565 patients (50% females). Women were older than men (76.6 ± 11.8 vs. 68.9 ± 13.4 years) and had higher prevalence of hypertension or hyperthyroidism, but lower prevalence of vascular disease, diabetes, renal disease, and cardiomyopathies than men. Overall, 17.6% of women and 25.1% of men were treated with any AAT. Women were treated with AADs more often than men in all age groups [adjusted subdistribution hazard ratio (aSHR) 1.223, 95% confidence interval (CI) 1.187-1.261]. Cardioversions were also performed less often on women than on men aged <65 years (aSHR 0.722, 95% CI 0.695-0.749), more often in patients ≥ 75 years (aSHR 1.166, 95% CI 1.108-1.227), while no difference between the sexes existed in patients aged 65-74 years. Ablations were performed less often in women aged <65 years (aSHR 0.908, 95% CI 0.826-0.998) and ≥75 years (aSHR 0.521, 95% CI 0.354-0.766), whereas there was no difference in patients aged 65-74 years.</p><p><strong>Conclusion: </strong>Women used more AAD than men in all age groups but underwent fewer cardioversion and ablation procedures when aged <65 years.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-03DOI: 10.1093/europace/euae228
Miroslav Boskovic, Jarle Jortveit, Marius Blørstad Haraldsen, Trygve Berge, Johan Engdahl, Maja-Lisa Løchen, Peter Schuster, Edvard Liljedahl Sandberg, Jostein Grimsmo, Dan Atar, Ole-Gunnar Anfinsen, Are Hugo Pripp, Bjørnar Leangen Grenne, Sigrun Halvorsen
Aims: Atrial fibrillation (AF) is a common arrhythmia, and many cases of AF may be undiagnosed. Whether screening for AF and subsequent treatment if AF is detected can improve long-term outcome remains an unsettled question. The primary aim of the NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial is to assess whether self-screening for AF with continuous electrocardiogram (ECG) for 3-7 days in individuals aged 65 years or older with at least one additional risk factor for stroke, and initiation of guideline-recommended therapy in patients with detected AF, will reduce the occurrence of stroke.
Methods and results: This study is a nationwide open, siteless, randomized, controlled trial. Individuals ≥65 years of age are randomly identified from the National Population Register of Norway and are invited to take a digital inclusion/exclusion test. Individuals passing the inclusion/exclusion test are randomized to either the intervention group or the control group. A total of 35 000 participants will be enrolled. In the intervention group, self-screening is performed continuously over 3-7 days at home with a patch ECG device (ECG247) at inclusion and after 12-18 months. If AF is detected, guideline-recommended therapy will be initiated. Patients will be followed up for 5 years through national health registries. The primary outcome is time to a first stroke (ischaemic or haemorrhagic stroke). The first participant in the NORSCREEN trial was enrolled on 1 September 2023.
Conclusion: The results from the NORSCREEN trial will provide new insights regarding the efficacy of digital siteless self-screening for AF with respect to stroke prevention in individuals at an increased risk of stroke.
{"title":"The NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial: rationale and design of a randomized controlled trial.","authors":"Miroslav Boskovic, Jarle Jortveit, Marius Blørstad Haraldsen, Trygve Berge, Johan Engdahl, Maja-Lisa Løchen, Peter Schuster, Edvard Liljedahl Sandberg, Jostein Grimsmo, Dan Atar, Ole-Gunnar Anfinsen, Are Hugo Pripp, Bjørnar Leangen Grenne, Sigrun Halvorsen","doi":"10.1093/europace/euae228","DOIUrl":"10.1093/europace/euae228","url":null,"abstract":"<p><strong>Aims: </strong>Atrial fibrillation (AF) is a common arrhythmia, and many cases of AF may be undiagnosed. Whether screening for AF and subsequent treatment if AF is detected can improve long-term outcome remains an unsettled question. The primary aim of the NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial is to assess whether self-screening for AF with continuous electrocardiogram (ECG) for 3-7 days in individuals aged 65 years or older with at least one additional risk factor for stroke, and initiation of guideline-recommended therapy in patients with detected AF, will reduce the occurrence of stroke.</p><p><strong>Methods and results: </strong>This study is a nationwide open, siteless, randomized, controlled trial. Individuals ≥65 years of age are randomly identified from the National Population Register of Norway and are invited to take a digital inclusion/exclusion test. Individuals passing the inclusion/exclusion test are randomized to either the intervention group or the control group. A total of 35 000 participants will be enrolled. In the intervention group, self-screening is performed continuously over 3-7 days at home with a patch ECG device (ECG247) at inclusion and after 12-18 months. If AF is detected, guideline-recommended therapy will be initiated. Patients will be followed up for 5 years through national health registries. The primary outcome is time to a first stroke (ischaemic or haemorrhagic stroke). The first participant in the NORSCREEN trial was enrolled on 1 September 2023.</p><p><strong>Conclusion: </strong>The results from the NORSCREEN trial will provide new insights regarding the efficacy of digital siteless self-screening for AF with respect to stroke prevention in individuals at an increased risk of stroke.</p><p><strong>Trial registration: </strong>Clinical trials: NCT05914883.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11448330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-03DOI: 10.1093/europace/euae260
Péter Perge, Nikola Petrovic, Zoltán Salló, Katalin Piros, Vivien Klaudia Nagy, Pál Ábrahám, István Osztheimer, Béla Merkely, László Gellér, Nándor Szegedi
Aims: The predictive role of local impedance (LI) drop in lesion formation using a novel contact force sensing ablation catheter was recently described. The purpose of our current study was to assess the temporal characteristics of LI drop during ablation and its correlation with acute lesion efficacy.
Methods and results: Point-by-point pulmonary vein isolation was performed. The efficacy of applications was determined by pacing along the circular ablation line and assessing loss of capture. Local impedance, contact force, and catheter position data with high resolution were analysed and compared in successful and unsuccessful applications. Five hundred and fifty-nine successful and 84 unsuccessful applications were analysed. The successful applications showed higher baseline LI (P < 0.001) and larger LI drop during ablation (P < 0.001, for all). In case of unsuccessful applications, after a moderate but significant drop from baseline to the 2 s time point (153 vs. 145 Ω, P < 0.001), LI did not change further (P = 0.99). Contradictorily, in case of successful applications, the LI significantly decreased further (baseline-2 s-10 s: 161-150-141 Ω, P < 0.001 for all). The optimal cut-point for the LI drop indicating unsuccessful application was <9 Ω at the 4-s time point [AUC = 0.73 (0.67-0.76), P < 0.001]. Failing to reach this cut-point predicted unsuccessful applications [OR 3.82 (2.34-6.25); P < 0.001].
Conclusion: A rapid and enduring drop of the LI may predict effective lesion formation, while slightly changing or unchanged LI is associated with unsuccessful applications. A moderate LI drop during the first 4 s of radiofrequency application predicts ineffective radiofrequency delivery.
{"title":"Early rapid local impedance drop is associated with acute lesion efficacy during pulmonary vein isolation.","authors":"Péter Perge, Nikola Petrovic, Zoltán Salló, Katalin Piros, Vivien Klaudia Nagy, Pál Ábrahám, István Osztheimer, Béla Merkely, László Gellér, Nándor Szegedi","doi":"10.1093/europace/euae260","DOIUrl":"10.1093/europace/euae260","url":null,"abstract":"<p><strong>Aims: </strong>The predictive role of local impedance (LI) drop in lesion formation using a novel contact force sensing ablation catheter was recently described. The purpose of our current study was to assess the temporal characteristics of LI drop during ablation and its correlation with acute lesion efficacy.</p><p><strong>Methods and results: </strong>Point-by-point pulmonary vein isolation was performed. The efficacy of applications was determined by pacing along the circular ablation line and assessing loss of capture. Local impedance, contact force, and catheter position data with high resolution were analysed and compared in successful and unsuccessful applications. Five hundred and fifty-nine successful and 84 unsuccessful applications were analysed. The successful applications showed higher baseline LI (P < 0.001) and larger LI drop during ablation (P < 0.001, for all). In case of unsuccessful applications, after a moderate but significant drop from baseline to the 2 s time point (153 vs. 145 Ω, P < 0.001), LI did not change further (P = 0.99). Contradictorily, in case of successful applications, the LI significantly decreased further (baseline-2 s-10 s: 161-150-141 Ω, P < 0.001 for all). The optimal cut-point for the LI drop indicating unsuccessful application was <9 Ω at the 4-s time point [AUC = 0.73 (0.67-0.76), P < 0.001]. Failing to reach this cut-point predicted unsuccessful applications [OR 3.82 (2.34-6.25); P < 0.001].</p><p><strong>Conclusion: </strong>A rapid and enduring drop of the LI may predict effective lesion formation, while slightly changing or unchanged LI is associated with unsuccessful applications. A moderate LI drop during the first 4 s of radiofrequency application predicts ineffective radiofrequency delivery.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-03DOI: 10.1093/europace/euae254
Meye Bloothooft, Niels Voigt, Teun P de Boer
{"title":"Addressing SARS-CoV-2 viroporins with antiarrhythmic drugs.","authors":"Meye Bloothooft, Niels Voigt, Teun P de Boer","doi":"10.1093/europace/euae254","DOIUrl":"https://doi.org/10.1093/europace/euae254","url":null,"abstract":"","PeriodicalId":11981,"journal":{"name":"Europace","volume":"26 10","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11481343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-03DOI: 10.1093/europace/euae248
Piotr Futyma, Arian Sultan, Łukasz Zarębski, Guram Imnadze, Vera Maslova, Stefano Bordignon, Maria Kousta, Sven Knecht, Nikola Pavlović, Petr Peichl, Evgeny Lian, Thomas Kueffer, Daniel Scherr, Michael Pfeffer, Paweł Moskal, Gabriel Cismaru, Bor Antolič, Paweł Wałek, Shaojie Chen, Martin Martinek, Georgios Kollias, Michael Derndorfer, Sebastian Seidl, Boris Schmidt, Jakob Lüker, Daniel Steven, Philipp Sommer, Marek Jastrzębski, Josef Kautzner, Tobias Reichlin, Christian Sticherling, Helmut Pürerfellner, Andres Enriquez, Jonas Wörmann, Julian K R Chun
Aims: Advanced ablation strategies are needed to treat ventricular tachycardia (VT) and premature ventricular complexes (PVC) refractory to standard unipolar radiofrequency ablation (Uni-RFA). Bipolar radiofrequency catheter ablation (Bi-RFA) has emerged as a treatment option for refractory VT and PVC. Multicentre registry data on the use of Bi-RFA in the setting of refractory VT and PVC are lacking. The aim of this Bi-RFA registry is to determine its real-world safety, feasibility, and efficacy in patients with refractory VT/PVC.
Methods and results: Consecutive patients undergoing Bi-RFA at 16 European centres for recurring VT/PVC after at least one standard Uni-RFA were included. Second ablation catheter was used instead of a dispersive patch and was positioned at the opposite site of the ablation target. Between March 2021 and August 2024, 91 patients underwent 94 Bi-RFA procedures (74 males, age 62 ± 13, and prior Uni-RFA range 1-8). Indications were recurrence of PVC (n = 56), VT (n = 20), electrical storm (n = 13), or PVC-triggered ventricular fibrillation (n = 2). Procedural time was 160 ± 73 min, Bi-RFA time 426 ± 286 s, and mean Uni-RFA time 819 ± 697 s. Elimination of clinical VT/PVC was achieved in 67 (74%) patients and suppression of VT/PVC in a further 10 (11%) patients. In the remaining 14 patients (15%), no effect on VT/PVC was observed. Three major complications occurred: coronary artery occlusion, atrioventricular block, and arteriovenous fistula. Follow-up lasted 7 ± 8 months. Nineteen patients (61%) remained VT free. ≥80% PVC burden reduction was achieved in 45 (78%).
Conclusion: These real-world registry data indicate that Bi-RFA appears safe, is feasible, and is effective in the majority of patients with VT/PVC.
{"title":"Bipolar radiofrequency ablation of refractory ventricular arrhythmias: results from a multicentre network.","authors":"Piotr Futyma, Arian Sultan, Łukasz Zarębski, Guram Imnadze, Vera Maslova, Stefano Bordignon, Maria Kousta, Sven Knecht, Nikola Pavlović, Petr Peichl, Evgeny Lian, Thomas Kueffer, Daniel Scherr, Michael Pfeffer, Paweł Moskal, Gabriel Cismaru, Bor Antolič, Paweł Wałek, Shaojie Chen, Martin Martinek, Georgios Kollias, Michael Derndorfer, Sebastian Seidl, Boris Schmidt, Jakob Lüker, Daniel Steven, Philipp Sommer, Marek Jastrzębski, Josef Kautzner, Tobias Reichlin, Christian Sticherling, Helmut Pürerfellner, Andres Enriquez, Jonas Wörmann, Julian K R Chun","doi":"10.1093/europace/euae248","DOIUrl":"10.1093/europace/euae248","url":null,"abstract":"<p><strong>Aims: </strong>Advanced ablation strategies are needed to treat ventricular tachycardia (VT) and premature ventricular complexes (PVC) refractory to standard unipolar radiofrequency ablation (Uni-RFA). Bipolar radiofrequency catheter ablation (Bi-RFA) has emerged as a treatment option for refractory VT and PVC. Multicentre registry data on the use of Bi-RFA in the setting of refractory VT and PVC are lacking. The aim of this Bi-RFA registry is to determine its real-world safety, feasibility, and efficacy in patients with refractory VT/PVC.</p><p><strong>Methods and results: </strong>Consecutive patients undergoing Bi-RFA at 16 European centres for recurring VT/PVC after at least one standard Uni-RFA were included. Second ablation catheter was used instead of a dispersive patch and was positioned at the opposite site of the ablation target. Between March 2021 and August 2024, 91 patients underwent 94 Bi-RFA procedures (74 males, age 62 ± 13, and prior Uni-RFA range 1-8). Indications were recurrence of PVC (n = 56), VT (n = 20), electrical storm (n = 13), or PVC-triggered ventricular fibrillation (n = 2). Procedural time was 160 ± 73 min, Bi-RFA time 426 ± 286 s, and mean Uni-RFA time 819 ± 697 s. Elimination of clinical VT/PVC was achieved in 67 (74%) patients and suppression of VT/PVC in a further 10 (11%) patients. In the remaining 14 patients (15%), no effect on VT/PVC was observed. Three major complications occurred: coronary artery occlusion, atrioventricular block, and arteriovenous fistula. Follow-up lasted 7 ± 8 months. Nineteen patients (61%) remained VT free. ≥80% PVC burden reduction was achieved in 45 (78%).</p><p><strong>Conclusion: </strong>These real-world registry data indicate that Bi-RFA appears safe, is feasible, and is effective in the majority of patients with VT/PVC.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11495370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-03DOI: 10.1093/europace/euae251
Maarten A J De Smet, Clara François, Benjamin De Becker, Rene Tavernier, Jean-Benoît le Polain de Waroux, Sébastien Knecht, Mattias Duytschaever
{"title":"Intravascular haemolysis and acute kidney injury following atrial fibrillation ablation: a report using two different systems for pulsed field ablation.","authors":"Maarten A J De Smet, Clara François, Benjamin De Becker, Rene Tavernier, Jean-Benoît le Polain de Waroux, Sébastien Knecht, Mattias Duytschaever","doi":"10.1093/europace/euae251","DOIUrl":"10.1093/europace/euae251","url":null,"abstract":"","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-03DOI: 10.1093/europace/euae246
Domenico G Della Rocca, Antonio Sorgente, Luigi Pannone, María Cespón-Fernández, Giampaolo Vetta, Alexandre Almorad, Gezim Bala, Alvise Del Monte, Erwin Ströker, Juan Sieira, Ioannis Doundoulakis, Sahar Mouram, Charles Audiat, Cinzia Monaco, Sanghamitra Mohanty, Roberto Scacciavillani, Lorenzo Marcon, Kazutaka Nakasone, Wael Zaher, Ingrid Overeinder, Serge Boveda, Mark La Meir, Andrea Natale, Andrea Sarkozy, Carlo de Asmundis, Gian-Battista Chierchia
Aims: Rhythm control of non-paroxysmal atrial fibrillation (AF) is significantly more challenging, as a result of arrhythmia perpetuation promoting atrial substrate changes and AF maintenance. We describe a tailored ablation strategy targeting multiple left atrial (LA) sites via a pentaspline pulsed field ablation (PFA) catheter in persistent AF sustained beyond 6 months (PerAF > 6 m) and long-standing persistent AF (LSPAF).
Methods and results: The ablation protocol included the following stages: pulmonary vein antral and posterior wall isolation plus anterior roof line ablation (Stage 1); electrogram-guided substrate ablation (Stage 2); atrial tachyarrhythmia regionalization and ablation (Stage 3). Seventy-two [age:68 ± 10years, 61.1%males; AF history: 25 (18-45) months] patients with PerAF > 6 m (52.8%) and LSPAF (47.2%) underwent their first PFA via the FarapulseTM system. LA substrate ablation (Stage 1 and 2) led to AF termination in 95.8% of patients. AF organized into a left-sided atrial flutter (AFlu) in 46 (74.2%) patients. The PFA catheter was used to identify LA sites showing diastolic, low-voltage electrograms and entrainment from its splines was performed to confirm the pacing site was inside the AFlu circuit. Left AFlu termination was achieved in all cases via PFA delivery. Total procedural and LA dwell times were 112 ± 25 min and 59 ± 22 min, respectively. Major complications occurred in 2 (2.8%) patients. Single-procedure success rate was 74.6% after 14.9 ± 2.7 months of follow-up; AF-free survival was 89.2%.
Conclusion: In our cohort, PFA-based AF substrate ablation led to AF termination in 95.8% of cases. Very favourable clinical outcomes were observed during >1 year of follow-up.
背景和目的:非阵发性心房颤动(房颤)的节律控制明显更具挑战性,因为心律失常的持续会促进心房底质的改变和房颤的维持。我们介绍了针对持续房颤超过 6 个月(PerAF>6m)和长期持续房颤(LSPAF),通过五线脉冲场消融(PFA)导管针对多个左心房(LA)部位的定制消融策略:消融方案包括以下阶段:肺静脉前壁和后壁隔离加前顶线消融(第1阶段);电图引导下的基底消融(第2阶段);心房快速性心律失常区域化和消融(第3阶段):72名[年龄:68±10岁,61.1%男性;房颤病史:25(18-45)个月]PerAF>6m(52.8%)和LSPAF(47.2%)患者通过FarapulseTM系统接受了首次PFA。95.8%的患者通过 LA 基底消融(1 期和 2 期)终止了房颤。有 46 名患者(74.2%)的房颤发展为左心房扑动(AFlu)。使用 PFA 导管确定显示舒张期低电压电图的 LA 位点,并对其花键进行夹带,以确认起搏位点位于 AFlu 回路内。所有病例均通过 PFA 输送实现左房颤终止。手术总时间和 LA 驻留时间分别为 112±25 分钟和 59±22 分钟。2例(2.8%)患者出现了严重并发症。随访14.9±2.7个月后,单次手术成功率为74.6%;无房颤生存率为89.2%:在我们的队列中,95.8%的病例通过基于PFA的房颤基底消融术终止了房颤。在超过一年的随访中观察到了非常良好的临床结果。
{"title":"Multielectrode catheter-based pulsed field ablation of persistent and long-standing persistent atrial fibrillation.","authors":"Domenico G Della Rocca, Antonio Sorgente, Luigi Pannone, María Cespón-Fernández, Giampaolo Vetta, Alexandre Almorad, Gezim Bala, Alvise Del Monte, Erwin Ströker, Juan Sieira, Ioannis Doundoulakis, Sahar Mouram, Charles Audiat, Cinzia Monaco, Sanghamitra Mohanty, Roberto Scacciavillani, Lorenzo Marcon, Kazutaka Nakasone, Wael Zaher, Ingrid Overeinder, Serge Boveda, Mark La Meir, Andrea Natale, Andrea Sarkozy, Carlo de Asmundis, Gian-Battista Chierchia","doi":"10.1093/europace/euae246","DOIUrl":"10.1093/europace/euae246","url":null,"abstract":"<p><strong>Aims: </strong>Rhythm control of non-paroxysmal atrial fibrillation (AF) is significantly more challenging, as a result of arrhythmia perpetuation promoting atrial substrate changes and AF maintenance. We describe a tailored ablation strategy targeting multiple left atrial (LA) sites via a pentaspline pulsed field ablation (PFA) catheter in persistent AF sustained beyond 6 months (PerAF > 6 m) and long-standing persistent AF (LSPAF).</p><p><strong>Methods and results: </strong>The ablation protocol included the following stages: pulmonary vein antral and posterior wall isolation plus anterior roof line ablation (Stage 1); electrogram-guided substrate ablation (Stage 2); atrial tachyarrhythmia regionalization and ablation (Stage 3). Seventy-two [age:68 ± 10years, 61.1%males; AF history: 25 (18-45) months] patients with PerAF > 6 m (52.8%) and LSPAF (47.2%) underwent their first PFA via the FarapulseTM system. LA substrate ablation (Stage 1 and 2) led to AF termination in 95.8% of patients. AF organized into a left-sided atrial flutter (AFlu) in 46 (74.2%) patients. The PFA catheter was used to identify LA sites showing diastolic, low-voltage electrograms and entrainment from its splines was performed to confirm the pacing site was inside the AFlu circuit. Left AFlu termination was achieved in all cases via PFA delivery. Total procedural and LA dwell times were 112 ± 25 min and 59 ± 22 min, respectively. Major complications occurred in 2 (2.8%) patients. Single-procedure success rate was 74.6% after 14.9 ± 2.7 months of follow-up; AF-free survival was 89.2%.</p><p><strong>Conclusion: </strong>In our cohort, PFA-based AF substrate ablation led to AF termination in 95.8% of cases. Very favourable clinical outcomes were observed during >1 year of follow-up.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11498055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-03DOI: 10.1093/europace/euae253
Joseph Mayer, Jaffar Al-Sheikhli, Maria Niespialowska-Steuden, Ian Patchett, James Winter, Rafaella Siang, Nicolas Lellouche, Karthick Manoharan, Thanh Trung Phan, Justo Juliá Calvo, Andreu Porta-Sánchez, Ivo Roca Luque, John Silberbauer, Tarvinder Dhanjal
Aims: Differentiating near-field (NF) and far-field (FF) electrograms (EGMs) is crucial in identifying critical arrhythmogenic substrate during ventricular tachycardia (VT) ablation. A novel algorithm annotates NF-fractionated signals enabling EGM peak frequency (PF) determination using wavelet transformation. This study evaluated the algorithms' effectiveness in identifying critical components of the VT circuit during substrate mapping.
Methods and results: A multicentre, international cohort undergoing VT ablation was investigated. VT activation maps were used to demarcate the isthmus zone (IZ). Offline analysis was performed to evaluate the diagnostic performance of low-voltage area (LVA) PF substrate mapping. A total of 30 patients encompassing 198 935 EGMs were included. The IZ PF was significantly higher in sinus rhythm (SR) compared to right ventricular paced (RVp) substrate maps (234 Hz (195-294) vs. 197 Hz (166-220); P = 0.010). Compared to LVA PF, the IZ PF was significantly higher in both SR and RVp substrate maps (area under curve, AUC: 0.74 and 0.70, respectively). The LVA PF threshold of ≥200 Hz was optimal in SR maps (sensitivity 69%; specificity 64%) and RVp maps (sensitivity 60%; specificity 64%) in identifying the VT isthmus. In amiodarone-treated patients (n = 20), the SR substrate map IZ PF was significantly lower (222 Hz (186-257) vs. 303 Hz (244-375), P = 0.009) compared to amiodarone-naïve patients (n = 10). The ≥200 Hz LVA PF threshold resulted in an 80% freedom from VT with a trend towards reduced ablation lesions and radiofrequency times.
Conclusion: LVA PF substrate mapping identifies critical components of the VT circuit with an optimal threshold of ≥200 Hz. Isthmus PF is influenced by chronic amiodarone therapy with lower values observed during RV pacing.
背景:在室性心动过速(VT)消融过程中,区分近场(NF)和远场(FF)电图(EGM)对于识别关键致心律失常基质至关重要。一种新型算法可注释 NF 分馏信号,从而利用小波变换确定 EGM 峰频 (PF)。本研究评估了该算法在底物映射过程中识别 VT 电路关键组件的有效性:研究对象是接受 VT 消融术的多中心国际队列。VT 激活图用于划分峡部区(IZ)。进行离线分析以评估低电压区(LVA)PF 基底图的诊断性能:结果:共纳入了 30 名患者,共绘制了 198,935 个 EGMs。与右室起搏(RVp)基底图相比,窦性心律(SR)的 IZ PF 明显更高(234(195-294)Hz vs 197(166-220)Hz;P=0.010)。与 LVA PF 相比,SR 和 RVp 基底图中的 IZ PF 明显更高(AUC:分别为 0.74 和 0.70)。在 SR 基底图(灵敏度 69%;特异性 64%)和 RVp 基底图(灵敏度 60%;特异性 64%)中,≥200Hz 的 LVA PF 阈值是识别 VT 峡部的最佳阈值。在胺碘酮治疗的患者中(n=20),SR 基底图 IZ PF 与胺碘酮无效的患者(n=10)相比显著降低(222(186-257)Hz vs 303(244-375)Hz,p=0.009)。≥200Hz的LVA PF阈值可使80%的患者免于VT,并有减少消融病灶和射频时间的趋势:结论:LVA PF基底映射可识别VT电路的关键组成部分,其最佳阈值为≥200Hz。地峡 PF 受长期胺碘酮治疗的影响,在 RV 起搏时观察到的数值较低。
{"title":"Detailed analysis of electrogram peak frequency to guide ventricular tachycardia substrate mapping.","authors":"Joseph Mayer, Jaffar Al-Sheikhli, Maria Niespialowska-Steuden, Ian Patchett, James Winter, Rafaella Siang, Nicolas Lellouche, Karthick Manoharan, Thanh Trung Phan, Justo Juliá Calvo, Andreu Porta-Sánchez, Ivo Roca Luque, John Silberbauer, Tarvinder Dhanjal","doi":"10.1093/europace/euae253","DOIUrl":"10.1093/europace/euae253","url":null,"abstract":"<p><strong>Aims: </strong>Differentiating near-field (NF) and far-field (FF) electrograms (EGMs) is crucial in identifying critical arrhythmogenic substrate during ventricular tachycardia (VT) ablation. A novel algorithm annotates NF-fractionated signals enabling EGM peak frequency (PF) determination using wavelet transformation. This study evaluated the algorithms' effectiveness in identifying critical components of the VT circuit during substrate mapping.</p><p><strong>Methods and results: </strong>A multicentre, international cohort undergoing VT ablation was investigated. VT activation maps were used to demarcate the isthmus zone (IZ). Offline analysis was performed to evaluate the diagnostic performance of low-voltage area (LVA) PF substrate mapping. A total of 30 patients encompassing 198 935 EGMs were included. The IZ PF was significantly higher in sinus rhythm (SR) compared to right ventricular paced (RVp) substrate maps (234 Hz (195-294) vs. 197 Hz (166-220); P = 0.010). Compared to LVA PF, the IZ PF was significantly higher in both SR and RVp substrate maps (area under curve, AUC: 0.74 and 0.70, respectively). The LVA PF threshold of ≥200 Hz was optimal in SR maps (sensitivity 69%; specificity 64%) and RVp maps (sensitivity 60%; specificity 64%) in identifying the VT isthmus. In amiodarone-treated patients (n = 20), the SR substrate map IZ PF was significantly lower (222 Hz (186-257) vs. 303 Hz (244-375), P = 0.009) compared to amiodarone-naïve patients (n = 10). The ≥200 Hz LVA PF threshold resulted in an 80% freedom from VT with a trend towards reduced ablation lesions and radiofrequency times.</p><p><strong>Conclusion: </strong>LVA PF substrate mapping identifies critical components of the VT circuit with an optimal threshold of ≥200 Hz. Isthmus PF is influenced by chronic amiodarone therapy with lower values observed during RV pacing.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11481296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-03DOI: 10.1093/europace/euae233
Cédric Klein, Claude Kouakam, Arnaud Lazarus, Pascal de Groote, Christophe Bauters, Eloi Marijon, Frédéric Mouquet, Bruno Degand, Yves Guyomar, Jacques Mansourati, Christophe Leclercq, Laurence Guédon-Moreau
Aims: Integrating remote monitoring (RM) into existing healthcare practice for heart failure (HF) patients to improve clinical outcome remains challenging. The ECOST-CRT study compared the clinical outcome of a comprehensive RM scheme including a patient questionnaire capturing signs and symptoms of HF and notifications for HF specific parameters to traditional RM in patients with cardiac resynchronization therapy (CRT) devices.
Methods and results: Patients were randomized 1:1 to standard daily RM (notification for technical parameters and ventricular arrhythmias; control group) or comprehensive RM (adding a monthly symptom questionnaire and notifications for biventricular pacing, premature ventricular contraction, atrial arrhythmias; active group). The primary endpoint was all-cause mortality or hospitalization for worsening HF (WHF). Six hundred fifty-two patients (70.4 ± 10.3 years, 73% men, left ventricular ejection fraction 29.1 ± 7.6%, 68% CRT-Defibrillators, 32% CRT-Pacemakers) were enrolled. The COVID-19 pandemic caused an early termination of the study, so the mean follow-up duration was 18 ± 8 months. No statistically significant difference in the primary endpoint was found between the groups [59 (18.3%) control vs. 77 (23.3%) active group; log-rank test P = 0.13]. Among the secondary endpoints, the MLHF questionnaire showed a larger share of patients with improvement of quality of life compared to baseline in the active group (78%) vs. control (61%; P = 0.03).
Conclusion: The study does not support the notion that comprehensive RM, when compared to standard RM, in HF patients with CRT improves the clinical outcome of all-cause mortality or WHF hospitalizations. However, this study was underpowered due to an early termination and further trials are required.
{"title":"Comprehensive vs. standard remote monitoring of cardiac resynchronization devices in heart failure patients: results of the ECOST-CRT study.","authors":"Cédric Klein, Claude Kouakam, Arnaud Lazarus, Pascal de Groote, Christophe Bauters, Eloi Marijon, Frédéric Mouquet, Bruno Degand, Yves Guyomar, Jacques Mansourati, Christophe Leclercq, Laurence Guédon-Moreau","doi":"10.1093/europace/euae233","DOIUrl":"https://doi.org/10.1093/europace/euae233","url":null,"abstract":"<p><strong>Aims: </strong>Integrating remote monitoring (RM) into existing healthcare practice for heart failure (HF) patients to improve clinical outcome remains challenging. The ECOST-CRT study compared the clinical outcome of a comprehensive RM scheme including a patient questionnaire capturing signs and symptoms of HF and notifications for HF specific parameters to traditional RM in patients with cardiac resynchronization therapy (CRT) devices.</p><p><strong>Methods and results: </strong>Patients were randomized 1:1 to standard daily RM (notification for technical parameters and ventricular arrhythmias; control group) or comprehensive RM (adding a monthly symptom questionnaire and notifications for biventricular pacing, premature ventricular contraction, atrial arrhythmias; active group). The primary endpoint was all-cause mortality or hospitalization for worsening HF (WHF). Six hundred fifty-two patients (70.4 ± 10.3 years, 73% men, left ventricular ejection fraction 29.1 ± 7.6%, 68% CRT-Defibrillators, 32% CRT-Pacemakers) were enrolled. The COVID-19 pandemic caused an early termination of the study, so the mean follow-up duration was 18 ± 8 months. No statistically significant difference in the primary endpoint was found between the groups [59 (18.3%) control vs. 77 (23.3%) active group; log-rank test P = 0.13]. Among the secondary endpoints, the MLHF questionnaire showed a larger share of patients with improvement of quality of life compared to baseline in the active group (78%) vs. control (61%; P = 0.03).</p><p><strong>Conclusion: </strong>The study does not support the notion that comprehensive RM, when compared to standard RM, in HF patients with CRT improves the clinical outcome of all-cause mortality or WHF hospitalizations. However, this study was underpowered due to an early termination and further trials are required.</p><p><strong>Registration: </strong>Clinical Trials.gov Identifier: NCT03012490.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":"26 10","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}